LRRC15 Is a Novel Mesenchymal Protein and Stromal Target for Antibody–Drug Conjugates

间充质干细胞 结缔组织增生 间质细胞 癌症研究 医学 癌相关成纤维细胞 胰腺癌 肿瘤微环境 癌症 成纤维细胞活化蛋白 人口 癌细胞 病理 内科学 肿瘤细胞 环境卫生
作者
James W. Purcell,Sonia G. Tanlimco,Jonathan A. Hickson,Melvin Fox,Mien Sho,Lisa M. Durkin,Tamar Uziel,Rick Powers,Kelly Foster,Thomas P. McGonigal,Subashri Kumar,Josue A. Samayoa,Dong Zhang,Joann P. Palma,Sasmita Mishra,Diane L. Hollenbaugh,Kurt Gish,Susan E. Morgan-Lappe,Eric D. Hsi,Debra T. Chao
出处
期刊:Cancer Research [American Association for Cancer Research]
卷期号:78 (14): 4059-4072 被引量:233
标识
DOI:10.1158/0008-5472.can-18-0327
摘要

Abstract Progress in understanding tumor stromal biology has been constrained in part because cancer-associated fibroblasts (CAF) are a heterogeneous population with limited cell-type–specific protein markers. Using RNA expression profiling, we identified the membrane protein leucine-rich repeat containing 15 (LRRC15) as highly expressed in multiple solid tumor indications with limited normal tissue expression. LRRC15 was expressed on stromal fibroblasts in many solid tumors (e.g., breast, head and neck, lung, pancreatic) as well as directly on a subset of cancer cells of mesenchymal origin (e.g., sarcoma, melanoma, glioblastoma). LRRC15 expression was induced by TGFβ on activated fibroblasts (αSMA+) and on mesenchymal stem cells. These collective findings suggested LRRC15 as a novel CAF and mesenchymal marker with utility as a therapeutic target for the treatment of cancers with LRRC15-positive stromal desmoplasia or cancers of mesenchymal origin. ABBV-085 is a monomethyl auristatin E (MMAE)-containing antibody–drug conjugate (ADC) directed against LRRC15, and it demonstrated robust preclinical efficacy against LRRC15 stromal-positive/cancer-negative, and LRRC15 cancer-positive models as a monotherapy, or in combination with standard-of-care therapies. ABBV-085′s unique mechanism of action relied upon the cell-permeable properties of MMAE to preferentially kill cancer cells over LRRC15-positive CAF while also increasing immune infiltrate (e.g., F4/80+ macrophages) in the tumor microenvironment. In summary, these findings validate LRRC15 as a novel therapeutic target in multiple solid tumor indications and support the ongoing clinical development of the LRRC15-targeted ADC ABBV-085. Significance: These findings identify LRRC15 as a new marker of cancer-associated fibroblasts and cancers of mesenchymal origin and provide preclinical evidence for the efficacy of an antibody-drug conjugate targeting the tumor stroma. Cancer Res; 78(14); 4059–72. ©2018 AACR.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
xin完成签到,获得积分10
1秒前
1秒前
2秒前
12345676543发布了新的文献求助10
2秒前
yzb发布了新的文献求助10
3秒前
3秒前
3秒前
unique完成签到 ,获得积分10
4秒前
专注香芦完成签到 ,获得积分10
4秒前
岛岛主完成签到,获得积分10
5秒前
5秒前
5秒前
很有用完成签到,获得积分10
5秒前
5秒前
科研通AI6.4的应助被和平发展采纳,获得10
6秒前
淳于黎昕完成签到,获得积分10
6秒前
今后的应助被byemaxf采纳,获得10
6秒前
Ava的应助被认真的白昼采纳,获得10
7秒前
8秒前
岛岛主发布了新的文献求助10
8秒前
李爱国的应助被吴新月采纳,获得10
8秒前
9秒前
9秒前
DinosaurYi完成签到,获得积分10
9秒前
迷途完成签到,获得积分20
10秒前
大模型的应助被yzb采纳,获得10
10秒前
10秒前
LSY完成签到 ,获得积分10
10秒前
幸运8完成签到,获得积分10
10秒前
搞怪冷之发布了新的文献求助10
12秒前
途中发布了新的文献求助20
12秒前
12秒前
damai完成签到,获得积分10
13秒前
louiselin完成签到,获得积分10
13秒前
鱼鱼鱼发布了新的文献求助10
14秒前
14秒前
14秒前
15秒前
15秒前
米豆发布了新的文献求助10
15秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
Markov Decision Processes and Reinforcement Learning 700
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8171069
求助须知:如何正确求助?哪些是违规求助? 9563791
关于积分的说明 21772202
捐赠科研通 7762628
什么是DOI,文献DOI怎么找? 3430786
关于科研通互助平台的介绍 2554696
邀请新用户注册赠送积分活动 2475672